GERD in Children With Cystic Fibrosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age2-18
SponsorDuke University
About this trial
The purpose of this study is to evaluate the prevalence of gastroesophageal reflux disease (GERD) symptoms in pediatric patients with cystic fibrosis using the Gastroesophageal Symptom Assessment Scale (GSAS) and the impact of stopping anti-GERD therapy on the GERD symptoms reported.
Eligibility criteria
Qualifiers
Children 2-18 years of age with a confirmed CF diagnosis by either a positive sweat test or 2 disease causing CFTR mutations.
Signed consent
Disqualifiers
Declining to participate in the study or sign consent
History of severe GERD per gastroenterology diagnosis and documentation
GSAS score >80
Trial design
Treatments tested in this trial
- Discontinuation of GERD therapy
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Duke University
Lead sponsor
Cystic Fibrosis Foundation
Collaborator
Source ClinicalTrials.gov